Targeting neuroblastoma cells with a new T cell therapy
Official title: Assessing the efficacy of a ROR1:PD-L1:CD2 multispecific T cell engager in ROR1-positive and -negative neuroblastoma models
Funded at Seattle Children's Hospital · NIH-10946469 · Data updated 2026-11-12
This study is exploring a new way to help kids with neuroblastoma by using a special treatment that helps their immune system find and attack the cancer cells more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $503,194 |
| NIH project number | 1R21CA292221-01 |
| Project ID | NIH-10946469 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with neuroblastoma, particularly those with recurrent or resistant forms of the disease.
✕Less likely to help
Patients with neuroblastoma who do not express the targeted proteins (ROR1 and PD-L1) may not benefit from this treatment.
What this research studies
This research investigates a novel approach to treating neuroblastoma, a challenging childhood cancer, by using a multispecific T cell engager that targets specific proteins on cancer cells. The therapy aims to redirect the body's immune T cells to recognize and destroy neuroblastoma cells by binding to ROR1, PD-L1, and CD3. By leveraging the immune system's ability to fight cancer, this approach hopes to improve outcomes for patients with recurrent neuroblastoma. The study will assess the effectiveness and safety of this treatment in preclinical models before potential clinical application.
Why it matters
Potential benefit: If successful, this research could lead to a new immunotherapy option for children with neuroblastoma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results with similar T cell therapies, indicating potential for success with this novel approach.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Olson, James M — Seattle Children's Hospital
- Study coordinator: Olson, James M
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.